EGRX vs. ALRN, KZR, EQ, CKPT, KRON, AEON, CALC, CARM, MURA, and ANVS
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Aileron Therapeutics (ALRN), Kezar Life Sciences (KZR), Equillium (EQ), Checkpoint Therapeutics (CKPT), Kronos Bio (KRON), AEON Biopharma (AEON), CalciMedica (CALC), Carisma Therapeutics (CARM), Mural Oncology (MURA), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
Eagle Pharmaceuticals' return on equity of 0.00% beat Aileron Therapeutics' return on equity.
Eagle Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 257.14%. Aileron Therapeutics has a consensus price target of $19.00, indicating a potential upside of 403.98%. Given Aileron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aileron Therapeutics is more favorable than Eagle Pharmaceuticals.
In the previous week, Aileron Therapeutics had 5 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Aileron Therapeutics and 1 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.94 beat Aileron Therapeutics' score of 0.50 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Aileron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Eagle Pharmaceuticals received 200 more outperform votes than Aileron Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave Eagle Pharmaceuticals an outperform vote while only 66.88% of users gave Aileron Therapeutics an outperform vote.
Eagle Pharmaceuticals has higher revenue and earnings than Aileron Therapeutics. Aileron Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eagle Pharmaceuticals beats Aileron Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
